Stockscreener 앱 받기
37.00
0.51%
-0.19
시간 외 거래:
36.93
-0.07
-0.19%
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge - TipRanks
Alkermes plc (ALKS) Stock Analysis: Uncovering a 21% Upside Potential in Biopharmaceutical Innovation - DirectorsTalk Interviews
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises - MSN
Alkermes plc stock (IE00B56GVS15): M&A deal with Avadel and fresh analyst signals put focus on futur - AD HOC NEWS
Alkermes plc stock (IE00B56GVS15): focus shifts after oncology spin-off and latest quarterly figures - AD HOC NEWS
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline - TipRanks
T. Rowe Price (NASDAQ: ALKS) holds 4.66M shares, 2.8% stake - Stock Titan
Alkermes Reports Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia - Sleep Review
What is HC Wainwright's Estimate for Alkermes Q2 Earnings? - MarketBeat
Alkermes plc $ALKS Shares Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Alkermes stock hits 52-week high at $38.94 By Investing.com - Investing.com South Africa
Alkermes plc stock (IE00B56GVS15): Baird raises price target to $48 - AD HOC NEWS
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Alkermes reports encouraging data from Phase III study of Lumryz - Clinical Trials Arena
Alkermes stock hits 52-week high at $38.94 - Investing.com
ALKS Maintained by Baird -- Price Target Raised to $48.00 - GuruFocus
Alkermes (NASDAQ:ALKS) Price Target Raised to $48.00 - MarketBeat
Alkermes Gains Strength On Strong Execution And Strategic Diversification - RTTNews
Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH - Citeline News & Insights
Alkermes Earnings Surprise Keeps Nasdaq Composite Watching - Kalkine Media
Alkermes posts late-stage trial win for Lumryz in new sleep disorder - MSN
Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings - simplywall.st
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles - Benzinga
Investors Can Find Comfort In Alkermes' (NASDAQ:ALKS) Earnings Quality - 富途牛牛
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023 - Quantisnow
Positive Phase 3 Results for Alkermes (ALKS) LUMRYZ in Treating Hypersomnia - GuruFocus
Alkermes (ALKS) Shares Rise on Positive Sleep Disorder Therapy T - GuruFocus
Alkermes stock maintains Buy rating on positive sleep disorder trial By Investing.com - Investing.com South Africa
Alkermes stock maintains Buy rating on positive sleep disorder trial - Investing.com
Alkermes reports positive phase 3 trial results for LUMRYZ - Investing.com UK
Alkermes Announces Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia, Plans FDA Submission by End of 2026 - Minichart
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia - BioSpace
Alkermes Reports Positive Phase 3 Results for LUMRYZ - TipRanks
Alkermes reports positive phase 3 trial results for LUMRYZ By Investing.com - Investing.com South Africa
Alkermes Announces Positive Phase 3 REVITALYZ Results for LUMRYZ, Plans sNDA Filing by End of 2026 - TradingView
Alkermes (Nasdaq: ALKS) reports strong phase 3 LUMRYZ results in idiopathic hypersomnia - Stock Titan
Alkermes announces positive topline results from Revitalyz phase 3 study evaluating Lumryz - marketscreener.com
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
Discipline and Rules-Based Execution in ALKS Response - Stock Traders Daily
Alkermes plc (ALKS) Stock Analysis: Exploring a 30% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
Horizon Investments LLC Has $92,000 Stock Position in Alkermes plc $ALKS - MarketBeat
Danske Bank A S Sells 32,271 Shares of Alkermes plc $ALKS - MarketBeat
Alkermes (ALKS) Q1 2026 Earnings Transcript - AOL.com
Alkermes plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ALKS) 2026-05-07 - Seeking Alpha
Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market - TipRanks
Alkermes price target raised to $48 from $42 at UBS - TipRanks
Alkermes price target raised to $50 from $45 at Needham - TipRanks
Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results - Benzinga
0.65%
자본화:
|
볼륨(24시간):